Promedior
Bristol-Myers Squibb makes big pharma deals
September 1, 2015Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis
Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
